after I buy. Its the only way I can figure out why everything I touch goes down.
I TOLD YOU SO.
ATRS had no choice but to raise cash since they don't know if the FDA will approve the epi-pen. I dislike companies that raise cash at a lower share price then the previous raise. What a piece of junk.
a big news announcement from ATRS. Still looking,
Tomorrow or Friday is 60 days from filing the response to the CRL for Sumatriptan. The FDA normally responds within 60 days for a minor deficiency ANDA. The underwriters will use the volume to sell the additional 3 million shares. The recent shorting from $3 - $2.40 & the announcement is all planned ahead of time to get the secondary done.
Thats right. If they had news & FDA approval you wouldn't have the opportunity to get it at $2.10.
I listed SRPT as one of my two stock picks in the yearly challenge. I sold out of SRPT early in the year since I didn't like the way things were headed. I knew things had changed with the appointment of a new president but I kept looking for reasons to not invest. I missed out on a 65% gain today even though I knew it was going to move higher.
The same thing goes for ATRS. I know its going to move higher once they gain approval for the epi-pen. I can stand on the sidelines & look for reasons to not invest or I can follow my instincts.
I know he was touting how smart Deerfield was for buying the secondary. Is Deerfield also smart for selling?
Are these guys nuts? They get an annual bonus based on meeting certain goals. You don't need a special bonus & its another slap in the face of investors.
The current response is to let looters burn down the city. Bunch of idiots.
I won't be surprised for it to trade down to $2 but we're only a month away from a possible approval for the epi-pen so its hard to not take a position. If the epi-pen is approved then its hard to believe ATRS is worth less then $4 a share.
Everything is positive but no details. He considers 2015 the first year of Otrexup launch. I guess the first year was an expensive practice. More excuses.
QST - Phase III trial to start in 3rd quarter.
QSM - Nothing
Epipen - Still waiting for FDA decision. Anticipate 3rd qtr. Doesn't expect a 3rd entry until 2021 at earliest. Look for 10% of generic epipen revenues going to ATRS.
Sumatriptan - Waiting for imminent approval notice.
The plate is pretty full - Doesn't plan to expand the pipeline.
On another note - Golf got caught short due to rain so I was able to make it home for the presentation.
I give the drug all day long to pediatrics (oral) & adults (IV) before taking them back to surgery. No monitors or O2 is necessary. Its not a dangerous drug. The warnings are overkill unless the individual is also taking narcotics.
The stock could go lower since the market is comprised of a bunch of scared idiots. SO credit rating & divy are stable & anyone who says differently doesn't know the facts.
unless Hobb's bows out & lets Fickenscher do the presentation. Hobb's will stutter & umm his way through the presentation like the bumbling ill prepared corporate president we know all to well.
Hobb's involvement with Delcath should have eliminated his consideration as president of ATRS. Who can trust the guy after that disaster?
Managements main goal is to keep the doors open. These guys have big salaries & they don't get a paycheck if they run out of cash. The shareprice is a secondary concern.
You've pretty much answered your own question. The .70 move is the cost that the underwriters need in order to find investors for a money losing speculative biotech.
The shareprices recent move is just a well orchestrated trade.